|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||169.33 - 170.73|
|52 Week Range||138.83 - 191.10|
|PE Ratio (TTM)||15.48|
|Forward Dividend & Yield||4.60 (2.71%)|
|1y Target Est||N/A|
Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the current dealmaking environment on Wall Street, as M&A and IPO activity heat up. Is it the sign of a market top, as some analysts are warning?
GE isn’t the only household name I’m worried about. There is another popular dividend stock showing some very similar signs.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Roche Holding Ltd Genusssch. and Johnson & Johnson (PFE-US, BMY-US, GSK-US, CELG-US, GILD-US, ABBV-US, BIIB-US, ALXN-US, RHHVF-US ... Read more (Read more...)
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last month, growth of ETFs holding AMGN is favorable, with net inflows of $17.19 billion.
In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amgen, Inc. Here are 5 ETFs with the largest exposure to AMGN-US. Comparing the performance and risk of Amgen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
Shares of Amgen Inc (NASDAQ:AMGN) will begin trading ex-dividend in 3 days. To qualify for the dividend check of $1.15 per share, investors must have owned the shares prior toRead More...
Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Of the 31 analysts tracking Celgene (CELG) in November 2017, 11 analysts recommended a “strong buy” while eight analysts recommended a “buy.”
Attention dividend hunters! Amgen Inc (NASDAQ:AMGN) will be distributing its dividend of $1.15 per share in 7 days time, on the 08 December 2017, and will start trading ex-dividend onRead More...
Let’s talk about the only “market timing” strategy that actually works in practice – buying a stock before it announces a dividend hike.
In 3Q17, Amgen’s (AMGN) Enbrel generated revenues of around $1.36 billion, which reflected ~6% growth on year-over-year (or YoY) basis and ~7% growth on a quarter-over-quarter basis.